-
Je něco špatně v tomto záznamu ?
Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection
I. Murínová, M. Švidrnoch, T. Gucký, D. Řezáč, J. Hlaváč, O. Slanař, M. Šíma
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
PubMed Central
od 2016
Europe PubMed Central
od 2016 do Před 1 rokem
ProQuest Central
od 2012-02-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2012-02-01 do Před 6 měsíci
- MeSH
- antibakteriální látky * farmakokinetika aplikace a dávkování MeSH
- bakteriální infekce * farmakoterapie MeSH
- biologické modely * MeSH
- dospělí MeSH
- intravenózní infuze MeSH
- lidé středního věku MeSH
- lidé MeSH
- meropenem * farmakokinetika aplikace a dávkování MeSH
- metoda Monte Carlo MeSH
- monitorování léčiv metody MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. METHODS: A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. RESULTS: The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). CONCLUSIONS: A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively.
Department of Applied Pharmacy Faculty of Pharmacy Masaryk University Brno Czech Republic
Department of Clinical Pharmacy Military University Hospital Prague Prague Czech Republic
Laboratory of Pharmacology and Toxicology AGEL Laboratories Nový Jičín Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014277
- 003
- CZ-PrNML
- 005
- 20240905134345.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ejhpharm-2022-003535 $2 doi
- 035 __
- $a (PubMed)36307183
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Murínová, Irena $u Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czech Republic $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
- 245 10
- $a Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection / $c I. Murínová, M. Švidrnoch, T. Gucký, D. Řezáč, J. Hlaváč, O. Slanař, M. Šíma
- 520 9_
- $a OBJECTIVES: The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. METHODS: A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. RESULTS: The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). CONCLUSIONS: A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively.
- 650 12
- $a meropenem $x farmakokinetika $x aplikace a dávkování $7 D000077731
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a antibakteriální látky $x farmakokinetika $x aplikace a dávkování $7 D000900
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a bakteriální infekce $x farmakoterapie $7 D001424
- 650 12
- $a biologické modely $7 D008954
- 650 _2
- $a metoda Monte Carlo $7 D009010
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a intravenózní infuze $7 D007262
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Švidrnoch, Martin $u Laboratory of Pharmacology and Toxicology, AGEL Laboratories, Nový Jičín, Czech Republic
- 700 1_
- $a Gucký, Tomáš $u Laboratory of Pharmacology and Toxicology, AGEL Laboratories, Nový Jičín, Czech Republic
- 700 1_
- $a Řezáč, David $u Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Hlaváč, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic martin.sima@lf1.cuni.cz $1 https://orcid.org/000000026541738X $7 xx0222901
- 773 0_
- $w MED00200143 $t European journal of hospital pharmacy $x 2047-9956 $g Roč. 31, č. 3 (2024), s. 253-258
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36307183 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134339 $b ABA008
- 999 __
- $a ok $b bmc $g 2143835 $s 1226143
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 31 $c 3 $d 253-258 $e 20240423 $i 2047-9956 $m European journal of hospital pharmacy $n Eur J Hosp Pharm $x MED00200143
- LZP __
- $a Pubmed-20240725
